Maximum quantity allowed is 999
请选择数量
CAS RN: 57248-88-1 | 產品號碼: D3921
Disodium Pamidronate
×
![]()
×
* 以上價格已含運費關稅等但一些需要海運以及乾冰運輸的產品除外,詳情請與
當地經銷商
洽詢。
* TCI會時常優化儲存條件,儲存溫度請以在線目錄為準，敬請留意。
補充產品訊息:
Previously this product had been labeled as a hydrate form both in product name and molecular formula. The hydrate form had no exclusive CAS RN and used to share the same CAS RN as the anhydrous form.
To avoid any misleading information and since moisture in product is considered as an impurity, we have decided to remove the term 'Hydrate' from product name and 'xH2O' from the molecular formula for such products.
Please use it at ease since there is no difference in product quality, even if you see the previous indications on a part of label.
| 產品號碼 | D3921 |
純度/分析方法 
|
>95.0%(T) |
| 分子式 / 分子量 | C__3H__9NNa__2O__7P__2 = 279.03 |
| 外觀與形狀（20°C） | Solid |
| 儲存條件
|
Refrigerated (0-10°C) |
| 應避免的情況 | Heat Sensitive |
| 包裝和容器
|
100MG-Glass Bottle with Plastic Insert （閲覽圖片）, 1G-Glass Bottle with Plastic Insert （閲覽圖片） |
| CAS RN | 57248-88-1 |
| 相關CAS RN
|
109552-15-0&40391-99-9 |
| Reaxys-RN | 6459607 |
| PubChem Substance ID | 87561576 |
| Merck Index(14) | 7003 |
| MDL編號 | MFCD11045314 |
產品規格
| Appearance | White to Almost white powder to crystal |
| Purity(Nonaqueous Titration) | min. 95.0 %(calcd.on anh.substance) |
| Water | max. 25.0 % |
性質
GHS
| 圖形表示 |
|
| 信號詞 | Warning |
| 危險性說明 | H302 : Harmful if swallowed. H371 : May cause damage to organs. |
| 防範說明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P308 + P311 : IF exposed or concerned: Call a POISON CENTER/doctor. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. P405 : Store locked up. |
相關法規
| RTECS # | SZ6525000 |
運輸資料
| HS編碼* | 2931.49-900 |
Application
Reviews of pharmacology
References
- Pamidronate: A Review of its Pharmacological Properties and Therapeutic Efficacy in Resorptive Bone Disease
- A. Fitton, D. McTavish, Drugs 1991, 41, 289.
- Structure-Activity Relationships for Inhibition of Farnesyl Diphosphate Synthase in Vitro and Inhibition of Bone Resorption in Vivo by Nitrogen-Containing Bisphosphonates
- J. E. Dunford, K. Thompson, F. P. Coxon, S. P. Luckman, F. M. Hahn, C. D. Poulter, F. H. Ebetino, M. J. Rogers, J Pharmacol. Exp. Ther. 2001, 296, 235.
考研文獻
產品介紹報導
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。